Constellation Brands
STZ
$115.67
+2.08%
Constellation Brands is the largest alcoholic beverage supplier in the United States, operating across beer, wine, and spirits, with more than 90% of revenue derived from Mexican beer imports under top-selling brands Modelo and Corona, complemented by a legacy wine and spirits portfolio that has been actively pruned. The company holds exclusive US rights to these Mexican beer brands, giving it a distinct competitive moat in the high-margin imported beer segment, while its 10% stake in Canopy Growth and a 50/50 glass manufacturing joint venture with Owens-Illinois in Mexico round out its strategic positioning. The current investor narrative is dominated by a sharp divergence between operational strength and stock price weakness: beer volumes and buybacks remain robust, yet the shares have slumped to multi-year lows amid disappointing forward profit guidance, a broader alcohol industry "growth hangover" marked by defensive consolidation, and tariff-related cost uncertainty on Mexican imports. Management's raised guidance and aggressive repurchase activity have led some analysts to argue the stock is undervalued near these levels, but the market remains focused on margin compression risks and slowing consumer demand in the alcoholic beverage category.…
STZ
Constellation Brands
$115.67
Related headlines
Investment Opinion: Should I buy STZ Today?
The synthesized recommendation is a Hold, balancing deep value and strong cash flow against significant near-term headwinds and negative momentum. The analyst consensus rating of 'buy' with an average target price of $163.35 implies 44.7% upside, but this optimism may be stale given the recent guidance miss and the stock's 19.67% one-year decline. The core thesis is that STZ is a high-quality defensive name trading at a distressed valuation, but the market is demanding a higher risk premium until revenue stabilizes and margin pressures ease.
Supporting evidence includes the forward PE of 9.20x, which is less than half the sector average, and a PS ratio of 3.03x that is near historical lows. Revenue growth has turned negative, with a 3.26% year-over-year decline in the most recent quarter, but the beer segment remains dominant and profitable, with a gross margin of 54.29% and an operating margin of 31.33%. Free cash flow is strong at $1.83 billion TTM, supporting a 2.58% dividend yield and aggressive buybacks ($223.8 million in the latest quarter). The implied upside to the analyst average target is substantial, but the low target of $110 suggests limited downside according to analysts.
Key risks that could invalidate the thesis include a breakdown below the 52-week low of $111.54, which would signal a deeper repricing, and further revenue declines if consumer demand weakens. Tariff-related cost pressures could compress margins, and the industry's defensive consolidation may lead to increased competition. The rating would upgrade to Buy if the stock stabilizes above $120 and revenue growth turns positive, or downgrade to Sell if it breaks below $110 with accelerating revenue declines. Relative to its history and peers, STZ appears undervalued on a forward basis, but the market is pricing in significant uncertainty, making it a value play with above-average risk.
Sign up to view all
STZ 12-Month Price Forecast
The forward-looking view is neutral with medium confidence, as the stock is deeply undervalued on a forward basis but faces significant near-term headwinds. The base case (55% probability) sees the stock trading in a range of $120-$140, reflecting stabilization without a clear catalyst. The bull case (25%) hinges on an earnings recovery and multiple expansion, while the bear case (20%) risks a breakdown below $110 if fundamentals worsen. Key factors include the wide gap between trailing and forward PE, which suggests the market expects a recovery, but the recent revenue decline and guidance miss cast doubt on that expectation. I would upgrade to bullish if revenue growth turns positive and margins expand, and downgrade to bearish if the stock breaks below $110 with accelerating declines.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Constellation Brands's 12-month outlook, with a consensus price target around $162.04 and implied upside of +40.1% versus the current price.
Average Target
$162.04
0 analysts
Implied Upside
+40.1%
vs. current price
Analyst Count
—
covering this stock
Price Range
$110 - $209
Analyst target range
The stock is covered by 23 analysts with a consensus recommendation of "buy" and a recommendation mean of 2.04 on a scale where 1 is a strong buy and 5 is a strong sell, indicating a moderately bullish stance despite the stock's severe underperformance. The average target price is $163.35, which implies a staggering 44.7% upside from the current price of $112.87, a gap that reflects either significant undervaluation or stale analyst estimates that have not yet been revised downward to reflect the recent guidance miss and price decline. The consensus is clearly leaning bullish, but the magnitude of the implied upside suggests that analysts may be anchored to pre-decline valuations and could be slow to adjust their targets, creating a risk of further downgrades if the fundamental picture does not improve.
The target price range spans from a low of $110.00 to a high of $209.00, a spread of $99 or roughly 88% of the current price, which signals very high uncertainty and disagreement among analysts about the company's prospects. The high target of $209 assumes a full recovery in earnings growth, successful navigation of tariff pressures, and multiple expansion back toward historical averages, while the low target of $110 is essentially at the current price and prices in continued margin compression, revenue declines, and a prolonged period of underperformance. Recent institutional ratings show a mix of holds and buys with no recent upgrades or downgrades, as firms like JP Morgan (Neutral), UBS (Buy), Barclays (Equal Weight), and Citigroup (Buy) have maintained their positions, suggesting that analysts are in a wait-and-see mode ahead of the next earnings report; the wide target spread and lack of recent rating changes indicate that conviction is low and the stock is likely to remain volatile until clearer fundamental signals emerge.
Drowning in data?
Find the real signal!
Bulls vs Bears: STZ Investment Factors
The bear case currently has stronger evidence due to the severe technical downtrend, revenue contraction, and disappointing guidance, which have driven the stock to multi-year lows. However, the bull case is supported by deep value metrics, strong cash flow, and a significant analyst target upside, creating a classic value-versus-momentum tension. The most critical factor is whether the company can stabilize revenue and deliver on its forward earnings guidance; if it does, the low multiple could expand, but if not, the stock may remain a value trap. The divergence between operational strength in beer and stock price weakness highlights the market's focus on margin compression and slowing consumer demand. Ultimately, the resolution of tariff uncertainties and the next earnings report will likely determine the stock's direction.
Bullish
- Deep Value on Forward Earnings: The forward PE of 9.20x is less than half the trailing PE of 16.41x and roughly 60% below the Consumer Defensive sector average in the low-to-mid 20s. This implies the market expects a significant earnings recovery, and if the company delivers on its estimated EPS of $15.44, the stock is deeply undervalued.
- Strong Cash Generation and Buybacks: Trailing twelve-month free cash flow is $1.83 billion, and the company repurchased $223.8 million of stock in the most recent quarter. With a dividend yield of 2.58% and a payout ratio of 42.43%, the capital return program is sustainable and provides downside support.
- Analyst Consensus and Target Upside: 23 analysts rate the stock a 'buy' with a recommendation mean of 2.04, and the average target price of $163.35 implies 44.7% upside from the current price of $112.87. Even the low target of $110 is only 2.5% below the current price, suggesting limited downside according to analysts.
- Beer Segment Dominance and Moat: The beer segment generated $2.28 billion in the most recent quarter, over 93% of total revenue, driven by exclusive US rights to Modelo and Corona. This high-margin imported beer business provides a competitive moat and pricing power.
Bearish
- Severe Downtrend and Technical Weakness: The stock is down 19.67% over the past year and trades just 2.3% above its 52-week low of $111.54, with a 1-month decline of 12.74% and a 6-month loss of 25.35%. This falling-knife pattern indicates persistent selling pressure and a lack of buyer interest.
- Revenue Contraction and Margin Volatility: Most recent quarterly revenue declined 3.26% year-over-year to $2.43 billion, and net income fell from $502.8 million in Q3 2026 to $201.8 million in Q4 2026 before recovering. This volatility in earnings and the top-line decline raise concerns about growth sustainability.
- Disappointing Forward Guidance: The stock dropped after Q4 earnings despite a beat, due to forward profit guidance that missed Wall Street expectations. This suggests management sees near-term challenges, and analysts may need to revise their optimistic targets downward.
- Industry Headwinds and Consolidation: The alcohol industry is experiencing a 'growth hangover' with slowing consumer demand and fading pricing power, evidenced by a $60 billion defensive merger. This macro backdrop could pressure STZ's volumes and pricing, especially in the wine and spirits segment.
STZ Technical Analysis
Constellation Brands is in a sustained and severe downtrend, with the stock down 19.67% over the past year and trading at just 112.87, which represents only 2.3% above its 52-week low of 111.54 and a staggering 33.1% below its 52-week high of 168.6. This positioning near the bottom of the 52-week range signals that the stock is in a falling-knife scenario rather than a value opportunity, as the market has consistently punished the shares despite fundamental support. The current price sits at approximately 2.3% of the way up from the 52-week low, meaning there is virtually no cushion before a breakdown to new lows, and the stock has lost more than a third of its value from peak levels.
Short-term momentum is deeply negative and accelerating to the downside, with a 1-month decline of 12.74%, a 3-month drop of 17.89%, and a 6-month loss of 25.35%, all of which are significantly worse than the 1-year decline of 19.67%, indicating that selling pressure has intensified in recent months. The relative strength metrics confirm this underperformance: STZ has lagged the S&P 500 by 13.33 percentage points over the past month, 21.23 points over three months, and a staggering 42.70 points over six months, while the S&P 500 itself gained 15.01% over the past year. This persistent and widening divergence from the broader market suggests that the weakness is company-specific rather than macro-driven, and the lack of any meaningful bounce despite deeply oversold conditions points to a market that has lost confidence in the near-term earnings trajectory.
Key technical levels are starkly defined: the 52-week low of 111.54 serves as the critical support zone, and a breakdown below this level would likely trigger further selling and signal a deeper repricing of the equity story. The 52-week high of 168.6 represents formidable resistance, and reclaiming even a fraction of that ground would require a fundamental catalyst such as an earnings beat or a positive guidance revision. With a beta of just 0.4, STZ is significantly less volatile than the broader market, which means the magnitude of its decline is even more notable given that it typically moves only 40% as much as SPY; this low beta also implies that any recovery will likely be gradual rather than sharp, and position sizing should account for the stock's defensive characteristics even as it trades at distressed levels.
Beta
0.43
0.43x market volatility
Max Drawdown
-32.3%
Largest decline past year
52-Week Range
$111-$169
Price range past year
Annual Return
-16.6%
Cumulative gain past year
| Period | STZ Return | S&P 500 |
|---|---|---|
| 1m | -9.8% | +1.2% |
| 3m | -11.3% | +4.5% |
| 6m | -29.1% | +14.6% |
| 1y | -16.6% | +16.0% |
| ytd | -18.1% | +14.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
STZ Fundamental Analysis
Revenue is showing signs of stagnation and mild contraction, with the most recent quarter (ending May 2026) generating $2.43 billion, a decline of 3.26% year-over-year, following $1.92 billion in the prior quarter and $2.22 billion in the quarter before that. The beer segment remains the dominant driver at $2.28 billion, dwarfing the wine and spirits segment at just $149 million, which means overall growth is almost entirely dependent on Mexican beer brands like Modelo and Corona. The year-over-year revenue decline is concerning for a consumer staples company that has historically grown mid-single digits, and it suggests that the post-pandemic alcohol demand normalization and potential consumer trade-down are weighing on volumes and pricing power.
Profitability remains solid but is showing some strain, with net income of $653.8 million in the most recent quarter and a net margin of 18.46%, while the gross margin stands at 51.55% on a trailing basis and 54.29% in the latest quarter. The operating margin of 31.33% is healthy for the beverage industry, but the quarterly progression reveals volatility: gross margin was 54.29% in Q1 2027, down from 53.23% in Q3 2026 and 52.80% in Q2 2026, while net income fell from $502.8 million in Q3 2026 to $201.8 million in Q4 2026 before recovering to $653.8 million. The Q4 2026 net income of $201.8 million represented a net margin of just 10.51%, a sharp compression from the 22.62% net margin in Q3 2026, highlighting the earnings volatility that has spooked investors and contributed to the stock's decline.
Balance sheet health is adequate but not pristine, with a debt-to-equity ratio of 1.39, a current ratio of 1.08, and a cash position of only $96.6 million at the end of the most recent quarter, which is thin relative to the company's size. Free cash flow on a trailing twelve-month basis is $1.83 billion, and the most recent quarter generated $484.6 million in free cash flow from $661.8 million in operating cash flow against $177.2 million in capital expenditures, demonstrating that the business does generate substantial cash. However, the company returned $178.7 million in dividends and $223.8 million in stock repurchases during the quarter, and with a payout ratio of 42.43% and a dividend yield of 2.58%, the capital return program is meaningful but leaves limited room for error if cash flows deteriorate further; the ROE of 20.87% is strong and suggests efficient use of equity capital despite the leveraged balance sheet.
Quarterly Revenue
$2.4B
2026-05
Revenue YoY Growth
-3.3%
YoY Comparison
Gross Margin
54.3%
Latest Quarter
Free Cash Flow
$1.8B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is STZ Overvalued?
Because Constellation Brands is profitable with positive net income of $653.8 million in the most recent quarter, the PE ratio is the appropriate primary valuation metric, and the trailing PE of 16.41x compares to a forward PE of just 9.20x, a dramatic 44% compression that implies the market expects earnings to grow substantially over the next twelve months. This wide gap between trailing and forward multiples is unusual and suggests that either the market is pricing in a significant earnings recovery that has yet to materialize, or that the forward estimates are overly optimistic relative to the company's recent guidance, which missed expectations and triggered the stock's decline. The PEG ratio of -0.007 is not meaningful given the negative earnings growth trajectory, and the PS ratio of 3.03x and EV/EBITDA of 12.31x provide additional context for a company with a 51.55% gross margin and 31.33% operating margin.
Relative to the broader Consumer Defensive sector, which typically trades at a PE in the low-to-mid 20s, STZ's trailing PE of 16.41x represents a significant discount of roughly 25-30%, while the forward PE of 9.20x is less than half the sector average, implying a deep value signal if the earnings estimates prove accurate. The PS ratio of 3.03x is also below the sector median, and the EV/EBITDA of 12.31x is reasonable for a company with strong brand equity and consistent cash generation, though the discount is partially justified by the revenue decline, margin volatility, and the overhang of tariff and input cost pressures. The dividend yield of 2.58% is above the sector average and provides some downside support, but the market is clearly demanding a higher risk premium for the uncertainty surrounding the company's growth trajectory.
Looking at the stock's own historical valuation range, the current trailing PE of 16.41x is near the low end of its multi-year band, which has ranged from roughly 9x to over 80x during periods of earnings distortion, with more typical levels in the 15-25x range during stable periods. The PS ratio of 3.03x is also near historical lows, compared to levels above 10x in 2025 and 2026 when the stock traded at much higher prices, reflecting the severe de-rating that has occurred. This compression to the bottom of the historical range suggests the market is pricing in pessimistic expectations, and if the company can stabilize revenue and deliver on its forward earnings guidance, there is potential for multiple expansion; however, if the fundamental deterioration continues, the low multiple could prove to be a value trap rather than an opportunity.
PE
16.4x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 9x~46x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
12.3x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are significant, with a debt-to-equity ratio of 1.39 and a current ratio of just 1.08, indicating a leveraged balance sheet and limited liquidity cushion. The company's cash position of only $96.6 million is thin relative to its $19.3 billion market cap, and free cash flow, while robust at $1.83 billion TTM, could be pressured if revenue continues to decline. Revenue is highly concentrated in Mexican beer imports, which account for over 90% of sales, exposing the company to any disruption in that segment, such as supply chain issues or changes in consumer preferences. Additionally, earnings volatility is evident: net income swung from $502.8 million in Q3 2026 to $201.8 million in Q4 2026, a 60% drop, highlighting the risk of unpredictable profitability.
Market and competitive risks include the stock's premium valuation relative to its own history, with a trailing PE of 16.41x near the low end of its multi-year range, but the forward PE of 9.20x assumes an earnings recovery that may not materialize. The alcohol industry is facing a 'growth hangover' with slowing demand and defensive consolidation, as evidenced by a $60 billion merger, which could intensify competition and pressure pricing. Regulatory headwinds, such as potential tariffs on Mexican imports, pose a direct threat to margins, and the stock's low beta of 0.4 means it may underperform in a rising market, as seen by its 42.7% underperformance versus the S&P 500 over six months. Recent news highlights the industry's challenges, including Brown-Forman's buyout speculation and the broader consolidation trend, which could divert investor attention and capital away from STZ.
In a worst-case scenario, a breakdown below the 52-week low of $111.54 could trigger further selling, especially if the next earnings report misses expectations or tariffs are imposed. The analyst low target of $110 is only 2.5% below the current price, but if fundamentals deteriorate, the stock could fall to the 2024 lows or lower, potentially testing $90-$100, representing a 11-20% decline from current levels. The maximum drawdown over the past period was -32.34%, indicating that a similar drop from the recent high of $168.6 would imply a price near $114, but a more severe scenario could see a 30-40% decline from current levels if revenue declines accelerate and margins compress further. Investors could lose 20-30% from the current price in such an adverse scenario, with the 52-week low serving as a critical support level that, if broken, could lead to a deeper repricing.
FAQ
The key risks include financial, competitive, macro, and company-specific factors. Financially, the debt-to-equity ratio of 1.39 and current ratio of 1.08 indicate a leveraged balance sheet with limited liquidity, and a cash position of only $96.6 million leaves little room for error. Competitively, the alcohol industry is consolidating defensively, and STZ faces potential market share loss in a slowing demand environment. Macro risks include tariffs on Mexican imports, which could compress margins, and a low beta of 0.4 that may cause underperformance in a rising market. Company-specific risks include earnings volatility, as seen in the net income drop from $502.8 million to $201.8 million in Q4 2026, and the risk of a breakdown below the 52-week low of $111.54. Ranked by severity, the tariff risk and revenue decline are most immediate, followed by balance sheet leverage.
The 12-month forecast includes three scenarios: bull case (25% probability) with a target range of $163-$209, base case (55%) with $120-$140, and bear case (20%) with $90-$110. The base case is most likely, assuming revenue declines moderate and margins stabilize, leading to a trading range around current levels. The bull case requires an earnings recovery and multiple expansion, while the bear case involves a breakdown below $110 due to accelerating declines. The key assumption behind the base case is that the company avoids major tariff disruptions and maintains its dividend and buyback programs. Analyst targets average $163.35, but the wide range from $110 to $209 reflects high uncertainty.
STZ appears undervalued on a forward basis, with a forward PE of 9.20x compared to a trailing PE of 16.41x and a sector average in the low-to-mid 20s. The PS ratio of 3.03x is also near historical lows, and the EV/EBITDA of 12.31x is reasonable for a company with strong brand equity. However, the discount is partially justified by the 3.26% revenue decline and margin volatility, and the market is pricing in a pessimistic scenario. If the company meets its estimated EPS of $15.44, the stock could re-rate higher, but if estimates are cut, the low multiple could persist. Relative to its own history, the valuation is at the bottom of the range, suggesting limited downside but also a lack of near-term catalysts.
STZ presents a mixed risk/reward profile: the forward PE of 9.20x and 44.7% upside to the analyst average target of $163.35 suggest deep value, but the stock is down 19.67% over the past year and trades just 2.3% above its 52-week low, indicating significant momentum risk. The biggest downside risk is a breakdown below $111.54, which could lead to further losses, while the upside depends on revenue stabilization and margin recovery. For value investors with a long-term horizon, the stock may be attractive at these levels, but for short-term traders, the falling-knife pattern is a warning. A good buy would require confirmation of a bottom, such as a reclaim of $120 or a positive earnings surprise.
STZ is more suitable for long-term investment, given its defensive characteristics, low beta of 0.4, and strong cash flow generation of $1.83 billion TTM. The stock's severe downtrend and negative momentum make it risky for short-term trading, as it could break below the 52-week low of $111.54. The dividend yield of 2.58% and payout ratio of 42.43% provide income, and the buyback program supports long-term value. However, earnings visibility is low due to revenue declines and margin volatility, so a minimum holding period of 2-3 years is suggested to allow for a potential recovery. Short-term traders should wait for a technical confirmation of a bottom before entering.
